HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives

Yagi, Asami; Ueda, Yutaka; Kimura, Tadashi

doi:10.1016/j.vaccine.2024.03.080

Vaccine

2024

DOI: 10.1016/j.vaccine.2024.03.080

|View full text |Cite

HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives

Asami Yagi,

Yutaka Ueda,

Tadashi Kimura

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Cost‐effectiveness analysis of 9‐valent human papillomavirus vaccine combined with screening for cervical cancer in Japan

Takamoto,

Aso,

Ishida

et al. 2024

Intl J Gynecology & Obste

View full text Add to dashboard Cite

ObjectiveIn Japan, the current coverage rate of human papillomavirus (HPV) vaccination is only 30%, and the rate of biennial cervical screening is 40%. The Japanese Government has attempted to increase the coverage of HPV vaccination and cervical screening. We analyzed the cost‐effectiveness of the 9‐valent HPV vaccine and cervical screening in Japan.MethodsA yearly cycle Markov model with 15 health states was created to evaluate the cost‐effectiveness of the 9‐valent HPV vaccination and cervical screening in women aged 12–75 years. We considered four scenarios: 30% coverage of vaccination with 40% coverage of biennial screening (Scenario 1 representing the current Japanese situation), 70% (the highest proportion in 2013 in Japan) and 90% coverage of vaccination with 40% coverage of biennial screening (Scenarios 2 and 3, respectively), and 90% coverage of vaccination with 70% coverage of biennial screening (Scenarios 4). The incremental cost‐effectiveness ratio (ICER) was calculated as costs per quality‐adjusted life year (QALY) based on the perspective of the healthcare payer and compared with the benchmark for willingness to pay in Japan (41 700 USD per QALY). The cumulative morbidity and mortality in each scenario were analyzed using the Markov model.ResultsCompared with Scenario 1, the ICERs of Scenarios 2, 3, and 4 were 5382, 5321, and 8524 USD/QALY, respectively, which were lower than the benchmark for willingness to pay. As the coverage of HPV vaccination and cervical screening increased, the cumulative morbidity and mortality decreased.ConclusionIncreasing the coverage of the 9‐valent HPV vaccination and cervical screening is cost‐effective in Japan.

show abstract

Cost‐effectiveness analysis of 9‐valent human papillomavirus vaccine combined with screening for cervical cancer in Japan

Takamoto,

Aso,

Ishida

et al. 2024

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

Effect of information awareness on attitudes toward human papillomavirus vaccination intentions in Japan

Takahashi,

Kinoshita,

Shigemi

et al. 2025

Vaccine: X

View full text Add to dashboard Cite

Understanding Human Papillomavirus Vaccination Hesitancy in Japan: Social Media Analysis Using Large Language Models (Preprint)

Liu,

Niu,

Nagai-Tanima

et al. 2024

Journal of Medical Internet Research

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives

Cited by 4 publications

References 31 publications

Cost‐effectiveness analysis of 9‐valent human papillomavirus vaccine combined with screening for cervical cancer in Japan

Cost‐effectiveness analysis of 9‐valent human papillomavirus vaccine combined with screening for cervical cancer in Japan

Effect of information awareness on attitudes toward human papillomavirus vaccination intentions in Japan

Understanding Human Papillomavirus Vaccination Hesitancy in Japan: Social Media Analysis Using Large Language Models (Preprint)

Contact Info

Product

Resources

About